9.04.20
8 min. Read

New Teladongo merger details. Pear’s acquisitive study strategy.

Issue 068

Get E&O weekly. | Subscribe

Digital health research from Brian Dolan.

Welcome to E&O.

Last week I wrote about Amwell's IPO filing and the possible longterm repercussions of Amazon's move into voice biomarkers via its first wearable device, Halo. Here's what's happening this week:

  • Teladoc-Livongo revealed more information about their multi-billion dollar merger in a lengthy government

Paying Subscribers Only

It's a good one, too.
This digital health research is for paying Exits & Outcomes subscribers only. Subscribe now to read this article, get the weekly newsletter, and receive unrestricted access to past and future research from the Exits & Outcomes archives. Smash the link above or below to subscribe yourself -- or head over to our pricing page to subscribe your team or your whole company!
×

Full access to E&O's research and newsletters.

Get the subscribers-only newsletters + research reports + databases
$120M in secret health tech deals: Pearl Health, Amalgam Rx and more
1.23.23
5 min. Read
Florida Medicaid covers Pear. MedRhythms pivotal. Trials
1.20.23
6 min. Read
Akili layoffs, pipeline changes. DiGA price drop. Trials
1.13.23
7 min. Read
Big company benefits stack: T-Mobile
1.11.23
5 min. Read
Apple-Janssen Heartline study recruits 34K (not 150K). New DiGA.
1.06.23
5 min. Read
Trials. Omnibus excludes PDTs. ITC’s Apple Watch ban
12.23.22
6 min. Read
Six secret health tech deals
12.19.22
3 min. Read
New bill asks Medicaid to cover PDTs. More Apple-AliveCor.
12.16.22
7 min. Read
Big company benefits stack: Oracle
12.14.22
4 min. Read
New CPT applicants. ITC delays Apple-AliveCor one week.
12.09.22
7 min. Read
  • First
  • Previous
  • 1 of 29
  • Next
  • Last